Pharmesis International Ltd.

SGX:BFK Stock Report

Market Cap: S$20.4m

Pharmesis International Past Earnings Performance

Past criteria checks 0/6

Pharmesis International has been growing earnings at an average annual rate of 29%, while the Pharmaceuticals industry saw earnings growing at 10% annually. Revenues have been growing at an average rate of 3.1% per year.

Key information

29.0%

Earnings growth rate

32.5%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate3.1%
Return on equity-15.5%
Net Margin-17.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Is Pharmesis International (SGX:BFK) Using Too Much Debt?

Oct 10
Is Pharmesis International (SGX:BFK) Using Too Much Debt?

Would Pharmesis International (SGX:BFK) Be Better Off With Less Debt?

Dec 09
Would Pharmesis International (SGX:BFK) Be Better Off With Less Debt?

Health Check: How Prudently Does Pharmesis International (SGX:BFK) Use Debt?

Jun 08
Health Check: How Prudently Does Pharmesis International (SGX:BFK) Use Debt?

A Look At The Intrinsic Value Of Pharmesis International Ltd. (SGX:BFK)

Feb 23
A Look At The Intrinsic Value Of Pharmesis International Ltd. (SGX:BFK)

Revenue & Expenses Breakdown

How Pharmesis International makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SGX:BFK Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2442-7220
31 Mar 2444-6230
31 Dec 2346-5240
30 Sep 2352-3250
30 Jun 2359-2270
31 Mar 2355-3270
31 Dec 2250-4270
30 Sep 2248-3250
30 Jun 2246-2240
31 Mar 22500240
31 Dec 21531240
30 Sep 2153-1260
30 Jun 2153-2270
31 Mar 2150-4280
31 Dec 2047-6280
30 Sep 2045-13280
30 Jun 2038-16270
31 Mar 2039-17280
31 Dec 1937-18290
30 Sep 1942-7290
30 Jun 1948-4290
31 Mar 1957-2300
31 Dec 18641290
30 Sep 1867-2310
30 Jun 1871-1320
31 Mar 1870-2320
31 Dec 1770-2320
30 Sep 1772-4350
30 Jun 1771-4340
31 Mar 1770-4340
31 Dec 1669-5340
30 Sep 16650310
30 Jun 16640310
31 Mar 16631310
31 Dec 15622330
30 Sep 1561-2340
30 Jun 1563-3360
31 Mar 1561-3380
31 Dec 1461-4370
30 Sep 14631380
30 Jun 14622360
31 Mar 14631370
31 Dec 13650380

Quality Earnings: BFK is currently unprofitable.

Growing Profit Margin: BFK is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BFK is unprofitable, but has reduced losses over the past 5 years at a rate of 29% per year.

Accelerating Growth: Unable to compare BFK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BFK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.2%).


Return on Equity

High ROE: BFK has a negative Return on Equity (-15.52%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies